Hypereosinophilia is a rare paraneoplastic finding in malignant disease, particularly lung cancer. When it occurs, it is usually indicative of metastatic disease. We describe a 52-year-old male patient with paraneoplastic hypereosinophilia associated with primary adenocarcinoma of the right lower lobe and extensive metastatic disease.
medical history was unremarkable, except for chronic obstructive pulmonary disease (COPD) and long-standing, well-controlled epilepsy. Physical examination revealed a wasted patient with slow cognition not associated with any focal neurological deficits. Clinical examination revealed decreased breath sounds with dullness to percussion over the right lower lobe, and hepatomegaly extending 8 cm below the costal margin. Blood investigations showed marked elevation of his white cell count (peak level 114.18 × 10 9 /L) with an absolute eosinophilia ranging from 29.81 to 82.33 × 10 9 /L during the course of his admission. The bone marrow trephine confirmed marked eosinophilia, with no malignant infiltrate or evidence of clonal eosinophilic proliferation (absence of the FIP1L1/PDGFRA fusion gene on fluorescence in situ hybridisation (FISH) analysis). The chest radiograph showed a well-circumscribed lesion in the 
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right lower lobe with a pulmonary nodule in the left upper lobe (Fig. 1) . Computed tomography demonstrated a right lower lobe mass measuring 9.1 × 6.0 × 6.7 cm (Fig. 2) , bilateral pulmonary nodules, multiple liver lesions and a left adrenal mass. A core biopsy of the lung mass revealed nests of tumour cells with abundant eosinophilic cytoplasm and extensive tumour necrosis. No keratinisation or well-formed glands were noted. A panel of immunohistochemical stains was positive for CK7, MOC31 and thyroid transcription factor (TTF-1) in the malignant cells. Other stains performed, including p63, calretinin and WT1, excluded mesothelioma and squamous cell carcinoma. A final diagnosis of poorly differentiated adenocarcinoma of the lung was made.
High-dose corticosteroids and hydroxyurea were administered to the patient, with only modest reduction in the eosinophilia. He was referred to the palliative care team and died 47 days after admission.
Discussion
Paraneoplastic hypereosinophilia is rare. It has been described with many solid tumours including thyroid, breast, genitourinary, gastrointestinal, hepatocellular and in both non-small-and small-cell lung carcinoma. [2] Several studies suggest that local production of cytokines (GM-CSF, IL-3, and IL-5) by tumour cells is the most likely mechanism, particularly IL-5, which is considered to be the most important eosinophilopoetin. [3] [4] [5] These cytokines are involved in eosinophil development and maturation, with predominantly IL-5 mobilising eosinophils from bone marrow into the blood.
Management of eosinophilia is best achieved by tumour reduction (surgery and/or chemotherapy). However, case reports suggest that this is not always feasible, as these patients usually have extensive metastases and poor outcomes. [3] [4] [5] 
Conclusion
Our case report illustrates paraneoplastic hypereosinophilia, a rare manifestation in primary lung cancer. As in other case reports, [3] [4] [5] this is associated with a poor prognosis.
Learning points:
• Hypereosinophilia may occur as a paraneoplastic phenomenon in primary lung cancer.
• Paraneoplastic hypereosinophilia portends a poor prognosis.
